Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quanterix ( (QTRX) ) has provided an announcement.
On November 20, 2025, Quanterix Corporation announced significant leadership changes to support its next phase of growth. Paul Meister and David Walt retired from the Board of Directors, while Garret Hampton and Alan Sachs were appointed as new members. Additionally, Bill Donnelly was named Executive Chair, and Jeffrey Elliott was appointed Lead Independent Director. These changes aim to strengthen Quanterix’s strategic initiatives, including expanding its biomarker menu and accelerating growth following the Akoya acquisition. The Board now comprises nine members, with a focus on advancing the company’s mission to improve health outcomes.
The most recent analyst rating on (QTRX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall stock score reflects significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. While the earnings call showed positive revenue growth and strategic integration, ongoing market weaknesses and valuation concerns weigh heavily on the score.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology allows researchers to detect and quantify biomarkers at concentrations far below traditional limits. The company recently expanded its portfolio by acquiring Akoya Biosciences, enhancing its capabilities in multiplexed tissue imaging with single-cell resolution.
Average Trading Volume: 558,080
Technical Sentiment Signal: Sell
Current Market Cap: $273.7M
Learn more about QTRX stock on TipRanks’ Stock Analysis page.